Literature DB >> 21508169

Increased CXC ligand 10 levels and gene expression in type 1 leprosy reactions.

David M Scollard1, Meher V Chaduvula, Alejandra Martinez, Natalie Fowlkes, Indira Nath, Barbara M Stryjewska, Michael T Kearney, Diana L Williams.   

Abstract

Type 1 reaction (T1R) is a systemic inflammatory syndrome causing substantial morbidity in leprosy. T1R results from spontaneously enhanced cellular immunity in borderline types of leprosy, but there are no established laboratory markers for the reaction. Preliminary studies have identified elevated circulating CXC ligand 10 (CXCL10) during T1R. Correlation of CXCL10 with clinical T1R was studied in repeated serum specimens obtained before, during, and after T1R. CXCL10 gene expression was assessed in biopsy specimens taken before and during T1R, and sections were stained for the cytokine using monoclonal antibodies. Sequential serum specimens revealed elevation of circulating CXCL10 associated with episodes of T1R (P = 0.0001) but no evidence of an earlier, predictive change in the level of the chemokine. Reverse transcriptase (RT)-PCR revealed elevated expression of CXCL10 transcripts during T1R, but not in patients who did not have T1R. No significant correlation between CXCL10 and gamma interferon (IFN-γ) mRNA levels was observed. Immunohistochemical staining of the skin biopsy specimens suggested an overall increase in CXCL10 but did not identify a particular strongly staining population of leukocytes. Increased CXCL10 in lesions and serum is characteristic of T1R. CXCL10 measurement offers new possibilities for laboratory diagnosis and monitoring of T1R. Studies of the regulation of CXCL10 may provide insight into the mechanisms of T1R and identify potential new drug targets for treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21508169      PMCID: PMC3122607          DOI: 10.1128/CVI.00042-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  25 in total

Review 1.  Chemokines in immunity.

Authors:  O Yoshie; T Imai; H Nomiyama
Journal:  Adv Immunol       Date:  2001       Impact factor: 3.543

2.  CXCR3 chemokine receptor distribution in normal and inflamed tissues: expression on activated lymphocytes, endothelial cells, and dendritic cells.

Authors:  M A García-López; F Sánchez-Madrid; J M Rodríguez-Frade; M Mellado; A Acevedo; M I García; J P Albar; C Martínez; M Marazuela
Journal:  Lab Invest       Date:  2001-03       Impact factor: 5.662

3.  IFN-gamma, but not IP-10, MCP-2 or IL-2 response to RD1 selected peptides associates to active tuberculosis.

Authors:  Delia Goletti; Alamelu Raja; Basirudeen Syed Ahamed Kabeer; Camilla Rodrigues; Archana Sodha; Ornella Butera; Stefania Carrara; Guy Vernet; Christophe Longuet; Giuseppe Ippolito; Satheesh Thangaraj; Marc Leportier; Enrico Girardi; Philippe Henri Lagrange
Journal:  J Infect       Date:  2010-05-12       Impact factor: 6.072

4.  CCL5, CXCL10 and CXCL11 chemokines in patients with active and stable relapsing-remitting multiple sclerosis.

Authors:  Adam Szczuciński; Jacek Losy
Journal:  Neuroimmunomodulation       Date:  2010-08-19       Impact factor: 2.492

5.  Mediators of innate and adaptive immune responses differentially affect immune restoration disease associated with Mycobacterium tuberculosis in HIV patients beginning antiretroviral therapy.

Authors:  Benjamin G Oliver; Julian H Elliott; Patricia Price; Michael Phillips; Vonthanak Saphonn; Mean Chhi Vun; John M Kaldor; David A Cooper; Martyn A French
Journal:  J Infect Dis       Date:  2010-10-26       Impact factor: 5.226

6.  Classification of leprosy according to immunity. A five-group system.

Authors:  D S Ridley; W H Jopling
Journal:  Int J Lepr Other Mycobact Dis       Date:  1966 Jul-Sep

7.  Cytokine mRNA expression in leprosy: a possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL).

Authors:  M O Moraes; E N Sarno; A S Almeida; B C Saraiva; J A Nery; R C Martins; E P Sampaio
Journal:  Scand J Immunol       Date:  1999-11       Impact factor: 3.487

8.  An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis.

Authors:  Matthew P R Berry; Christine M Graham; Finlay W McNab; Zhaohui Xu; Susannah A A Bloch; Tolu Oni; Katalin A Wilkinson; Romain Banchereau; Jason Skinner; Robert J Wilkinson; Charles Quinn; Derek Blankenship; Ranju Dhawan; John J Cush; Asuncion Mejias; Octavio Ramilo; Onn M Kon; Virginia Pascual; Jacques Banchereau; Damien Chaussabel; Anne O'Garra
Journal:  Nature       Date:  2010-08-19       Impact factor: 49.962

9.  Potential plasma markers of Type 1 and Type 2 leprosy reactions: a preliminary report.

Authors:  Mariane M Stefani; Jackeline G Guerra; Ana Lucia M Sousa; Mauricio B Costa; Maria Leide W Oliveira; Celina T Martelli; David M Scollard
Journal:  BMC Infect Dis       Date:  2009-05-27       Impact factor: 3.090

10.  A combined CXCL10, CXCL8 and H-FABP panel for the staging of human African trypanosomiasis patients.

Authors:  Alexandre Hainard; Natalia Tiberti; Xavier Robin; Veerle Lejon; Dieudonné Mumba Ngoyi; Enock Matovu; John Charles Enyaru; Catherine Fouda; Joseph Mathu Ndung'u; Frédérique Lisacek; Markus Müller; Natacha Turck; Jean-Charles Sanchez
Journal:  PLoS Negl Trop Dis       Date:  2009-06-16
View more
  18 in total

1.  Transcriptional changes that characterize the immune reactions of leprosy.

Authors:  Kathryn M Dupnik; Thomas B Bair; Andressa O Maia; Francianne M Amorim; Marcos R Costa; Tatjana S L Keesen; Joanna G Valverde; Maria do Carmo A P Queiroz; Lúcio L Medeiros; Nelly L de Lucena; Mary E Wilson; Mauricio L Nobre; Warren D Johnson; Selma M B Jeronimo
Journal:  J Infect Dis       Date:  2014-11-14       Impact factor: 5.226

2.  Field-Friendly Test for Monitoring Multiple Immune Response Markers during Onset and Treatment of Exacerbated Immunity in Leprosy.

Authors:  Paul L A M Corstjens; Anouk van Hooij; Elisa M Tjon Kon Fat; Susan J F van den Eeden; Louis Wilson; Annemieke Geluk
Journal:  Clin Vaccine Immunol       Date:  2016-06-06

3.  Longitudinal IP-10 Serum Levels Are Associated with the Course of Disease Activity and Remission in Patients with Rheumatoid Arthritis.

Authors:  Anouk van Hooij; Debbie M Boeters; Elisa M Tjon Kon Fat; Susan J F van den Eeden; Paul L A M Corstjens; Annette H M van der Helm-van Mil; Annemieke Geluk
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

Review 4.  Advances and hurdles on the way toward a leprosy vaccine.

Authors:  Malcolm S Duthie; Thomas P Gillis; Steven G Reed
Journal:  Hum Vaccin       Date:  2011-11-01

5.  Evaluation of gamma interferon (IFN-γ)-induced protein 10 responses for detection of cattle infected with Mycobacterium bovis: comparisons to IFN-γ responses.

Authors:  W R Waters; T C Thacker; B J Nonnecke; M V Palmer; I Schiller; B Oesch; H M Vordermeier; E Silva; D M Estes
Journal:  Clin Vaccine Immunol       Date:  2012-01-11

6.  Longitudinal immune responses and gene expression profiles in type 1 leprosy reactions.

Authors:  Annemieke Geluk; Krista E van Meijgaarden; Louis Wilson; Kidist Bobosha; Jolien J van der Ploeg-van Schip; Susan J F van den Eeden; Edwin Quinten; Karin Dijkman; Kees L M C Franken; Elisabeth M Haisma; Mariëlle C Haks; Colette L M van Hees; Tom H M Ottenhoff
Journal:  J Clin Immunol       Date:  2013-12-27       Impact factor: 8.317

7.  Serological responses to prednisolone treatment in leprosy reactions: study of TNF-α, antibodies to phenolic glycolipid-1, lipoarabinomanan, ceramide and S100-B.

Authors:  Renuka Raju; Sujai Suneetha; Rupendra S Jadhav; MeherVani Chaduvula; Sara Atkinson; Suman Jain; Leo H Visser; Loretta Das; Ravindra Panhalkar; Vidyagouri Shinde; Parphananda P Reddy; Pramila Barkataki; Diana Nj Lockwood; Wim H Van Brakel; Lavanya M Suneetha
Journal:  Lipids Health Dis       Date:  2014-07-28       Impact factor: 3.876

8.  Field-evaluation of a new lateral flow assay for detection of cellular and humoral immunity against Mycobacterium leprae.

Authors:  Kidist Bobosha; Elisa M Tjon Kon Fat; Susan J F van den Eeden; Yonas Bekele; Jolien J van der Ploeg-van Schip; Claudia J de Dood; Karin Dijkman; Kees L M C Franken; Louis Wilson; Abraham Aseffa; John S Spencer; Tom H M Ottenhoff; Paul L A M Corstjens; Annemieke Geluk
Journal:  PLoS Negl Trop Dis       Date:  2014-05-08

9.  A Missense LRRK2 Variant Is a Risk Factor for Excessive Inflammatory Responses in Leprosy.

Authors:  Vinicius M Fava; Jérémy Manry; Aurélie Cobat; Marianna Orlova; Nguyen Van Thuc; Nguyen Ngoc Ba; Vu Hong Thai; Laurent Abel; Alexandre Alcaïs; Erwin Schurr
Journal:  PLoS Negl Trop Dis       Date:  2016-02-04

10.  Is CXCL10/CXCR3 axis overexpression a better indicator of leprosy type 1 reaction than inducible nitric oxide synthase?

Authors:  Ira Sharma; Avninder Singh; Ashwani K Mishra; L C Singh; V Ramesh; Sunita Saxena
Journal:  Indian J Med Res       Date:  2015-12       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.